Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Kadcyla contains the active ingredient ado-trastuzumab emtansine, and it’s available only as a brand-name biologic drug. It doesn’t come in a biosimilar version. A biosimilar medication is a ...

Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.

In the study, Tukysa (tucatinib) given with Kadcyla (trastuzumab emtansine) improved progression-free survival (PFS) compared to Kadcyla plus placebo, and Seagen plans to submit the data to ...